Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
10.9% normal saline (control)----1件: 299
2Active Control----1件: 13
3Amitriptyline, fluoxetine and tramadol alone (control group)3件: Amitriptyline,
Fluoxetine,
Tramadol		3件: D00326 ,
D07448 ,
D08623 		3件: OPRM1,
SLC6A2,
SLC6A4 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle 💬1件: 78
4Boots High Strength Garlic Odour Controlled1件: Garlic1件: D12020 --1件: 299
5BPR277 ointment (controlled application)----1件: 160
6Carbidopa and Levodopa Controlled Release Tablets2件: Carbidopa,
Levodopa		2件: D00059 ,
D00558 		6件: DDC,
DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬		16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬1件: 6
7Coenzyme Q-10 in Normal Control subjects1件: Ubidecarenone1件: D01065 --1件: 86
8Control----4件: 6, 46, 168, 299
9Control gel----1件: 36
10Control group----4件: 2, 13, 46, 70
11Control Group 0.9% Isotonic Saline----1件: 299
12Control intervention (no dexamethasone)1件: Dexamethasone1件: D00292 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 46
13Control multivitamin----1件: 299
14Controlled-release levodopa / carbidopa2件: Carbidopa,
Levodopa		2件: D00059 ,
D00558 		6件: DDC,
DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬		16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬1件: 6
15Cornstarch control1件: Starch, corn (Synonym: Lotrimin Daily Sweat and Odor Control)1件: D05297 --1件: 90
16Diazoxide choline controlled-release tablet2件: Choline,
Diazoxide		2件: D00294 ,
D07690 		2件: ABCC8,
KCNJ11 💬		4件: ABC transporters, GnRH secretion, Insulin secretion, Type II diabetes mellitus 💬1件: 193
17Epilim Chrono 200 Controlled Released tablets----1件: 256
18Epilim Chrono 300 Controlled Released tablets----1件: 256
19Epilim Chrono 500 Controlled Released tablets----1件: 256
20Group 1- Control Diet----1件: 97
21High dose vehicle control----1件: 46
22Infliximab Control1件: Infliximab1件: D02598 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 46
23Levodopa CR (controlled release)1件: Levodopa1件: D00059 5件: DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬		11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
24Low dose vehicle control----1件: 46
25Ropinirole controlled-release (REQUIP CR) for RLS1件: Ropinirole1件: D08489 3件: DRD2,
DRD3,
DRD4 💬		8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
26Sinemet® controlled release (Carbidopa/levodopa)2件: Carbidopa,
Levodopa		2件: D00059 ,
D00558 		6件: DDC,
DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬		16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬1件: 6
27Treatment vs control bread----1件: 97
28Vehice Control----1件: 96
29Vehicle Control----1件: 53